Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03623815
Other study ID # MS-IDREC-C2-2015-003
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 5, 2015
Est. completion date October 6, 2015

Study information

Verified date August 2018
Source University of Oxford
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the effect of frontal cortex transcranial direct current stimulation (tDCS) on the neural correlates of threat processing in healthy volunteers with a high level of trait anxiety. All participants received both active and sham tDCS and underwent a functional imaging scan whilst carrying out an attentional control task with fearful distractors.


Description:

There is a growing body of evidence suggesting that repeated administration of prefrontal transcranial direct current stimulation (tDCS) is a potential effective treatment for depression through restoring a left/right imbalance in frontal brain activity (Boggio et al., 2008; Loo et al., 2012) and improving top down control of anxiety responses.

An initial exploratory study was carried out in 2012 (Ironside et al 2015) to examine the effects of tDCS on emotional processing in healthy volunteers using a range of tasks and questionnaires. Using a dot probe task, which measures attention to happy or fearful faces, it was found that tDCS has the potential ability to reverse an attentional bias to fearful faces seen in the placebo group. This indicates that anxiety responses may be modified using tDCS and therefore this follow on study seeks to further explore the role of tDCS in trait anxiety and investigate the neural correlates of this with fMRI.

The present study uses behavioural and neuroimaging results to examine how tDCS affects emotional processing relevant to trait anxiety. A within-subjects design increases the power of the study, given limited resources to carry out extensive neuroimaging. Our working hypothesis is that tDCS may alter activity in cortical regions relevant to attentional control and anxiety.

The findings of this study will be used to determine parameters for future patient studies, involving participants with generalized anxiety disorder or major depression. The ultimate aim, explored through further studies, is to understand and improve how tDCS might be used in the treatment of these disorders.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date October 6, 2015
Est. primary completion date September 8, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Participant is willing and able to give informed consent for participation in the study.

- Healthy female adults, right handed, aged 18-45 years.

- Participants will be asked to fill in a pre-screening online anxiety questionnaire (STAI-T) and will be invited to participate in the study if they score high within the normal range on trait anxiety.

Exclusion Criteria:

- Any current significant medical condition.

- Any current or past psychological disorder (for example depression or anorexia).

- Any family history of extreme mood fluctuations (such as elated mood states)

- Any current medications (except for contraceptive treatment) or herbal remedies such as St John's wort.

- Any current pregnancy or likelihood of becoming pregnant during the study.

- Any participation in any other psychological or medical experiment involving taking any kind of drugs, within the last 3 months.

- Previous participation in a brain stimulation study will be taken into account and advice will be sought from the secondary supervisor on whether they should be included, based on the type of stimulation received, the location of the stimulation and the number of sessions. If the secondary supervisor advises that the nature of the stimulation previously received could affect the results of this study, the participant will not be included.

- Participants should not be claustrophobic, have a heart pacemaker, mechanical heart valve, mechanical implant such as an aneurysm clip, hip replacement, or any other pieces of metal that have accidentally entered their body.

- Any other contraindication to magnetic resonance imaging or transcranial current stimulation.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
transcranial direct current stimulation
Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulatory technique that uses weak electrical current to increase (with anodal) or decrease (with cathodal) the probability of brain activity in the stimulated region. This typically has acute effects relating to cortical activity levels which last up to one hour. This intervention delivers 20 minutes of 2mA bipolar balanced tDCS, with anodal tDCS delivered to the left dorsolateral prefrontal cortex (DLPFC) and simultaneously cathodal tDCS delivered to the right DLPFC. In the sham condition 40 seconds of stimulation is delivered.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
University of Oxford Medical Research Council

References & Publications (3)

Boggio PS, Zaghi S, Fregni F. Modulation of emotions associated with images of human pain using anodal transcranial direct current stimulation (tDCS). Neuropsychologia. 2009 Jan;47(1):212-7. doi: 10.1016/j.neuropsychologia.2008.07.022. Epub 2008 Aug 3. — View Citation

Ironside M, O'Shea J, Cowen PJ, Harmer CJ. Frontal Cortex Stimulation Reduces Vigilance to Threat: Implications for the Treatment of Depression and Anxiety. Biol Psychiatry. 2016 May 15;79(10):823-830. doi: 10.1016/j.biopsych.2015.06.012. Epub 2015 Jun 17. — View Citation

Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P. Transcranial direct current stimulation for depression: 3-week, randomised, sham-controlled trial. Br J Psychiatry. 2012 Jan;200(1):52-9. doi: 10.1192/bjp.bp.111.097634. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary The change in neural activity during an attentional control task after sham versus real tDCS A comparison of neural activity (blood oxygenation level dependent response) during an attentional control task after real versus sham tDCS. Outcome measure quantifies the change between measurement taken after real tDCS versus sham tDCS (order counterbalanced). The time period from the first measurement to the second and final measurement is no less than 30 days and no more than 60 days.
Secondary The change in accuracy in an attentional control task after sham versus real tDCS A comparison of behavioural test results (accuracy in attentional control task) after real versus sham tDCS. Outcome measure quantifies the change between measurement taken after real tDCS versus sham tDCS (order counterbalanced). The time period from the first measurement to the second and final measurement is no less than 30 days and no more than 60 days.
Secondary The change in reaction time in an attentional control task after sham versus real tDCS A comparison of behavioural test results (mean reaction time in milliseconds in attentional control task) after real versus sham tDCS. Outcome measure quantifies the change between measurement taken after real tDCS versus sham tDCS (order counterbalanced). The time period from the first measurement to the second and final measurement is no less than 30 days and no more than 60 days.
Secondary The change in self report anxiety after sham versus real tDCS Differences in anxiety symptoms after sham versus real tDCS will be quantified by the change in self report anxiety scores (State-Trait Anxiety Inventory (STAI)) after sham tDCS and real tDCS. Outcome measure quantifies the change between measurement taken after real tDCS versus sham tDCS (order counterbalanced). The time period from the first measurement to the second and final measurement is no less than 30 days and no more than 60 days.
Secondary The change in sadness/happiness after sham versus real tDCS Differences in sadness/happiness after sham versus real tDCS will be quantified by the change in self report visual analogue scale with sad at 0 and happy at 100 after sham tDCS and real tDCS. Outcome measure quantifies the change between measurement taken after real tDCS versus sham tDCS (order counterbalanced). The time period from the first measurement to the second and final measurement is no less than 30 days and no more than 60 days.
Secondary The change in hostility/friendliness after sham versus real tDCS Differences in hostility/friendliness after sham versus real tDCS will be quantified by the change in self report visual analogue scale with hostile at 0 and friendly at 100 after sham tDCS and real tDCS. Outcome measure quantifies the change between measurement taken after real tDCS versus sham tDCS (order counterbalanced). The time period from the first measurement to the second and final measurement is no less than 30 days and no more than 60 days.
Secondary The change in calmness/tenseness after sham versus real tDCS Differences in calmness/tenseness after sham versus real tDCS will be quantified by the change in self report visual analogue scale with calm at 0 and tense at 100 after sham tDCS and real tDCS. Outcome measure quantifies the change between measurement taken after real tDCS versus sham tDCS (order counterbalanced). The time period from the first measurement to the second and final measurement is no less than 30 days and no more than 60 days.
See also
  Status Clinical Trial Phase
Completed NCT05760482 - Evaluation of the Relationship Between Bruxism and Tryptophan Metabolites N/A
Recruiting NCT04368416 - Anxiety/Depression, Sleep and Alcohol in Elderly Anxiety/Depression, Sleep Disturbances and Alcohol Use Disorder in Elderly With Cognitive Complaints
Completed NCT01190774 - Anxiety Assessment Intervention in Dental Patients Phase 2/Phase 3
Not yet recruiting NCT06418269 - The Effect of Therapeutic Play on Anxiety and Fear Levels in Children With Diabetes N/A
Recruiting NCT06215456 - Virtual Reality to Reduce Periprocedural Anxiety During Invasive Coronary Angiography N/A
Completed NCT06114524 - Effect of Binaural Beats on Level of Anxiety and Toleration in Patients Undergoing Upper Gastrointestinal Endoscopy Without Sedation N/A
Completed NCT05316415 - The Effects of Music on the Anxiety and Sleep Quality of Pregnant Women on Bed Rest for a High-risk Pregnancy N/A
Recruiting NCT05433636 - Mindful Waiting Room N/A
Recruiting NCT06034496 - Cranial Electrotherapy Stimulation and Acute Stress N/A
Recruiting NCT06187090 - The Supplementation Therapy in Autism and Response to Treatment Study N/A
Completed NCT05499767 - HEPPI: Efficacy of a Cognitive-Emotional Intervention for Homebound Older Adults N/A
Not yet recruiting NCT03671317 - Medical Clowns for Pediatric Blood Draw N/A
Terminated NCT03227562 - Is Initial Response to Low Dose Risperidone Predictive for Outcome in Anxiety? Phase 3
Completed NCT04040036 - Effects of Virtual Reality on Pain, Fear and Anxiety During Blood Draw in Children Aged 5-12 Years Old N/A
Completed NCT04568551 - COVID-19-associated Anxiety of Pregnant Women for Anomalies, Stillbirth and Preterm Labor
Recruiting NCT06190184 - Viome Precision Nutritional Programs to Improve Clinical Outcomes for Mental Health Conditions N/A
Completed NCT04601545 - The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method N/A
Completed NCT06223412 - Visual Based Program and Climate Change N/A
Recruiting NCT04356638 - a Phase III Trial of Safety and Efficacy of Premedication With Dexmedetomidine and Midazolam in Pediatric Patients Phase 3
Completed NCT03977948 - Qualitative and Systemic Assessment of a Nurse Intervention an Inpatient Child and His or Her Parents